Vertex Pharmaceuticals Inc. Stock

On November 14, California-based Tensile Capital Management disclosed a buy of 160,559 shares of Vertex (NASDAQ:VERX) in the third quarter. Despite the expanded stake, the market value of the

Vertex Pharmaceuticals (NASDAQ: VRTX) has grown revenue and profit into the billions of dollars thanks to its expertise in the treatment of cystic fibrosis (CF). The company has developed a

Vertex Pharmaceuticals (NASDAQ: VRTX) has proven itself to be an excellent long-term investment, advancing 91% over the past five years. This is as the company has delivered steady growth in revenue

A lot can change in five years. Take Vertex Pharmaceuticals (NASDAQ: VRTX), for example. In late 2020, the big biotech company's approved products focused on one indication – cystic fibrosis (CF)

Vertex Pharmaceuticals (NASDAQ: VRTX) has not performed well for most of the year, and the company's latest quarterly update did nothing to turn things around. However, the market may be overlooking

Though it started the year strong, CRISPR Therapeutics (NASDAQ: CRSP) is experiencing a pullback. Over the past month, shares of the gene-editing specialist are down 23%. But there is plenty of

The stock of niche financial software company Vertex (NASDAQ: VERX) didn't get a very good start to the trading week at all. Its value fell by nearly 10% that day, due largely to a quarterly

I don't like the term "growth stock" all that much. Investors want their money to grow in some shape, form, or fashion with every stock they buy. However, I understand that textbook growth stocks

There are plenty of attractive stocks on the market. Some, though, have significantly underperformed their growth potential this year, making them attractive at their current levels.

This list

On Friday, Pennsylvania-based Conestoga Capital Advisors disclosed selling 855,435 shares of Vertex (NASDAQ:VERX), an estimated $24.8 million transaction based on average prices in the third

Equity markets are said to be forward looking. However, sometimes they fail to look far enough into the future by reacting too harshly to the challenges some companies face in the present. The good

As we enter the final three months of 2025, some investors may be looking for red-hot growth stocks with room to run. Whereas others may be searching for beaten-down stocks at compelling valuations

Investors who bought shares of Intuitive Surgical (NASDAQ: ISRG) or Vertex Pharmaceuticals (NASDAQ: VRTX) 20 years ago and held onto them are likely pleased with their decisions. Both companies have

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) have risen more than 2,000% over the past 20 years. Despite a terrific run-up, it's hard to find an investment bank analyst on Wall Street who expects

There is no sugarcoating it: Vertex Pharmaceuticals (NASDAQ: VRTX) has faced significant issues this year that have sunk its stock price. The company's shares are down 2% year-to-date, while the S&P

Small biopharma story stocks just aren't paying off like they used to. Maybe there are just too many of them, with each one working on a medical breakthrough that's statistically unlikely to even

Vertex Pharmaceuticals (NASDAQ: VRTX) is usually a market-beater, but it hasn't been so over the past year. The company's shares are down 18% over the trailing-12-month period due to a combination

Vertex Pharmaceuticals (NASDAQ: VRTX) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth

Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares

Even well-established drugmakers can lose significant market value overnight following a setback. That's what recently happened to Vertex Pharmaceuticals (NASDAQ: VRTX). The company's shares fell by

Vertex Pharmaceuticals (NASDAQ: VRTX) reported its second-quarter results after the market closed on Monday. Its shares plunged more than 17% in early trading on Tuesday.

Were Vertex's Q2 results

Is this finally the year CRISPR Therapeutics (NASDAQ: CRSP) bounces back? The biotech has lagged the market in recent years, but shares are up 50% over the past three months and have climbed 42%

Vertex Pharmaceuticals (NASDAQ: VRTX) has been a terrific stock to own over the past decade. The stock has outperformed the market over this period, thanks to consistent financial results and

What if you only had $1,000 to invest in stocks and had to put the money to work today? Which stocks would you buy? That's admittedly not an easy question to answer. I can think of lots of stocks

You're unlikely to have a warm-and-fuzzy feeling after buying some stocks. Instead, some stocks can keep you awake at night because of their high volatility and risk. The good news, though, is that